These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 24908096)

  • 1. Lee Silverman voice treatment versus standard NHS speech and language therapy versus control in Parkinson's disease (PD COMM pilot): study protocol for a randomized controlled trial.
    Sackley CM; Smith CH; Rick C; Brady MC; Ives N; Patel R; Roberts H; Dowling F; Jowett S; Wheatley K; Patel S; Kelly D; Sands G; Clarke C
    Trials; 2014 Jun; 15():213. PubMed ID: 24908096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multicentre, randomised controlled trial to compare the clinical and cost-effectiveness of Lee Silverman Voice Treatment versus standard NHS Speech and Language Therapy versus control in Parkinson's disease: a study protocol for a randomised controlled trial.
    Sackley CM; Rick C; Au P; Brady MC; Beaton G; Burton C; Caulfield M; Dickson S; Dowling F; Hughes M; Ives N; Jowett S; Masterson-Algar P; Nicoll A; Patel S; Smith CH; Woolley R; Clarke CE;
    Trials; 2020 May; 21(1):436. PubMed ID: 32460885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lee Silverman voice treatment versus NHS speech and language therapy versus control for dysarthria in people with Parkinson's disease (PD COMM): pragmatic, UK based, multicentre, three arm, parallel group, unblinded, randomised controlled trial.
    Sackley CM; Rick C; Brady MC; Woolley R; Burton C; Patel S; Masterson-Algar P; Nicoll A; Smith CH; Jowett S; Ives N; Beaton G; Dickson S; Ottridge R; Sharp L; Nankervis H; Clarke CE;
    BMJ; 2024 Jul; 386():e078341. PubMed ID: 38986549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lee Silverman Voice Treatment versus standard speech and language therapy versus control in Parkinson's disease: a pilot randomised controlled trial (PD COMM pilot).
    Sackley CM; Smith CH; Rick CE; Brady MC; Ives N; Patel S; Woolley R; Dowling F; Patel R; Roberts H; Jowett S; Wheatley K; Kelly D; Sands G; Clarke CE;
    Pilot Feasibility Stud; 2018; 4():30. PubMed ID: 29344405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lee Silverman Voice Treatment versus standard speech and language therapy versus control in Parkinson's disease: preliminary cost-consequence analysis of the PD COMM pilot randomised controlled trial.
    Scobie S; Jowett S; Lambe T; Patel S; Woolley R; Ives N; Rick C; Smith C; Brady MC; Clarke C; Sackley C
    Pilot Feasibility Stud; 2021 Aug; 7(1):154. PubMed ID: 34372913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Voice improvement following conventional speech therapy combined with singing intervention in people with Parkinson's disease: A three-arm randomised controlled trial.
    Mohseni Z; Mohamadi R; Habibi SAH; Saffarian A; Abolghasemi J
    Int J Lang Commun Disord; 2023; 58(5):1752-1767. PubMed ID: 37282797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parkinson's disease: speech and voice disorders and their treatment with the Lee Silverman Voice Treatment.
    Ramig LO; Fox C; Sapir S
    Semin Speech Lang; 2004 May; 25(2):169-80. PubMed ID: 15118943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The PD COMM trial: a protocol for the process evaluation of a randomised trial assessing the effectiveness of two types of SLT for people with Parkinson's disease.
    Masterson-Algar P; Burton CR; Brady MC; Nicoll A; Clarke CE; Rick C; Hughes M; Au P; Smith CH; Sackley CM
    Trials; 2017 Aug; 18(1):397. PubMed ID: 28851443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensive voice treatment in Parkinson's disease: Lee Silverman Voice Treatment.
    Sapir S; Ramig LO; Fox CM
    Expert Rev Neurother; 2011 Jun; 11(6):815-30. PubMed ID: 21651330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of an extended version of the lee silverman voice treatment on voice and speech in Parkinson's disease.
    Spielman J; Ramig LO; Mahler L; Halpern A; Gavin WJ
    Am J Speech Lang Pathol; 2007 May; 16(2):95-107. PubMed ID: 17456888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of vocal symptoms in Parkinson's disease: the Lee Silverman method].
    Dias AE; Limongi JC
    Arq Neuropsiquiatr; 2003 Mar; 61(1):61-6. PubMed ID: 12715021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design of the PERSPECTIVE study: PERsonalized SPEeCh Therapy for actIVE conversation in Parkinson's disease (randomized controlled trial).
    Maas JJL; De Vries NM; Bloem BR; Kalf JG
    Trials; 2022 Apr; 23(1):274. PubMed ID: 35395953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of speech and language therapy techniques for dysarthria in Parkinson's disease.
    Deane KH; Whurr R; Playford ED; Ben-Shlomo Y; Clarke CE
    Cochrane Database Syst Rev; 2001; (2):CD002814. PubMed ID: 11406045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Singing in groups for Parkinson's disease (SING-PD): a pilot study of group singing therapy for PD-related voice/speech disorders.
    Shih LC; Piel J; Warren A; Kraics L; Silver A; Vanderhorst V; Simon DK; Tarsy D
    Parkinsonism Relat Disord; 2012 Jun; 18(5):548-52. PubMed ID: 22436653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lee Silverman Voice Treatment for people with Parkinson's: audit of outcomes in a routine clinic.
    Wight S; Miller N
    Int J Lang Commun Disord; 2015; 50(2):215-25. PubMed ID: 25469736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Innovative technology for the assisted delivery of intensive voice treatment (LSVT®LOUD) for Parkinson disease.
    Halpern AE; Ramig LO; Matos CE; Petska-Cable JA; Spielman JL; Pogoda JM; Gilley PM; Sapir S; Bennett JK; McFarland DH
    Am J Speech Lang Pathol; 2012 Nov; 21(4):354-67. PubMed ID: 23071195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Speech and Language Therapy for Voice Problems in Parkinson's Disease: A Meta-Analysis.
    Xu H; Bao Z; Liang D; Li M; Wei M; Ge X; Liu J; Li J
    J Neuropsychiatry Clin Neurosci; 2020; 32(4):344-351. PubMed ID: 32374650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of intensive voice treatment on tone-language speakers with Parkinson's disease.
    Whitehill TL; Wong LL
    Clin Linguist Phon; 2007; 21(11-12):919-25. PubMed ID: 17972188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Computerised speech and language therapy or attention control added to usual care for people with long-term post-stroke aphasia: the Big CACTUS three-arm RCT.
    Palmer R; Dimairo M; Latimer N; Cross E; Brady M; Enderby P; Bowen A; Julious S; Harrison M; Alshreef A; Bradley E; Bhadhuri A; Chater T; Hughes H; Witts H; Herbert E; Cooper C
    Health Technol Assess; 2020 Apr; 24(19):1-176. PubMed ID: 32369007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multidimensional voice assessment after Lee Silverman Voice Therapy (LSVT
    Marchese MR; Proietti I; Longobardi Y; Mari G; Ausili Cefaro C; D'Alatri L
    Acta Otorhinolaryngol Ital; 2022 Aug; 42(4):348-354. PubMed ID: 36254651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.